A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer

Abstract This single-arm, multi-center clinical trial aimed to evaluate the safety, tolerability, DLT, recommended dose (RD), preliminary efficacy, and pharmacokinetics (PK) characteristics of lurbinectedin, a selective inhibitor of oncogenic transcription, in Chinese patients with advanced solid tu...

Full description

Bibliographic Details
Main Authors: Ying Cheng, Chunjiao Wu, Lin Wu, Jun Zhao, Yanqiu Zhao, Lulu Chen, Ying Xin, Liang Zhang, Pinhua Pan, Xingya Li, Juan Li, Xiaorong Dong, Ke Tang, Emei Gao, Fei Yu
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-54223-5

Internet

https://doi.org/10.1038/s41598-024-54223-5

Similar Items